Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV.

JAMA. 2011 Dec 28;306(24):2673-83. doi: 10.1001/jama.2011.1830. Epub 2011 Dec 12.

PMID:
22161946
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
[PubMed - indexed for MEDLINE]
3.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

PMID:
22682429
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

Elia J, Vetter VL.

Paediatr Drugs. 2010 Jun;12(3):165-75. doi: 10.2165/11532570-000000000-00000. Review.

PMID:
20481646
[PubMed - indexed for MEDLINE]
5.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
[PubMed - indexed for MEDLINE]
6.

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.

Peterson K, McDonagh MS, Fu R.

Psychopharmacology (Berl). 2008 Mar;197(1):1-11. Epub 2007 Nov 17. Review.

PMID:
18026719
[PubMed - indexed for MEDLINE]
7.

Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.

Hammerness PG, Surman CB, Chilton A.

Curr Psychiatry Rep. 2011 Oct;13(5):357-63. doi: 10.1007/s11920-011-0213-3. Review.

PMID:
21698412
[PubMed - indexed for MEDLINE]
8.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
[PubMed - indexed for MEDLINE]
9.

Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.

Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R.

Can J Cardiol. 2009 Nov;25(11):625-30. Review.

PMID:
19898693
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis.

Dahabreh IJ, Paulus JK.

JAMA. 2011 Mar 23;305(12):1225-33. doi: 10.1001/jama.2011.336. Review.

PMID:
21427375
[PubMed - indexed for MEDLINE]
11.

Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.

Winterstein AG.

Curr Psychiatry Rep. 2013 Aug;15(8):379. doi: 10.1007/s11920-013-0379-y. Review.

PMID:
23913135
[PubMed - indexed for MEDLINE]
12.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
[PubMed - indexed for MEDLINE]
13.

The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.

Najib J.

Clin Ther. 2009 Jan;31(1):142-76. doi: 10.1016/j.clinthera.2009.01.015. Review.

PMID:
19243715
[PubMed - indexed for MEDLINE]
14.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Epub 2008 Apr 1. Review.

PMID:
18384709
[PubMed - indexed for MEDLINE]
15.

[Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].

Golubchik P, Sever J, Weizman A.

Harefuah. 2011 Oct;150(10):788-90, 814. Review. Hebrew.

PMID:
22111124
[PubMed - indexed for MEDLINE]
16.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
[PubMed - indexed for MEDLINE]
17.

Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.

Mick E, McManus DD, Goldberg RJ.

Eur Neuropsychopharmacol. 2013 Jun;23(6):534-41. doi: 10.1016/j.euroneuro.2012.06.011. Epub 2012 Jul 15. Review.

PMID:
22796229
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies.

Armstrong EJ, Harskamp CT, Armstrong AW.

J Am Heart Assoc. 2013 Apr 4;2(2):e000062. doi: 10.1161/JAHA.113.000062. Review.

PMID:
23557749
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies.

Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI.

Circ Cardiovasc Qual Outcomes. 2013 Jan 1;6(1):99-109. doi: 10.1161/CIRCOUTCOMES.112.966903. Epub 2013 Jan 8. Review.

PMID:
23300267
[PubMed - indexed for MEDLINE]
Free Article
20.

Cardiovascular and neurological causes of sudden death after ischaemic stroke.

Sörös P, Hachinski V.

Lancet Neurol. 2012 Feb;11(2):179-88. doi: 10.1016/S1474-4422(11)70291-5. Review.

PMID:
22265213
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk